Maurizio A Leone, Maurizio Gelati, Daniela C Profico, Claudio Gobbi, Emanuele Pravatà, Massimiliano Copetti, Carlo Conti, Lucrezia Abate, Luigi Amoruso, Francesco Apollo, Rosario F Balzano, Ilaria Bicchi, Massimo Carella, Alessandro Ciampini, Carlo Colosimo, Paola Crociani, Giada D'Aloisio, Pietro Di Viesti, Daniela Ferrari, Danilo Fogli, Andrea Fontana, Domenico Frondizi, Valentina Grespi, Jens Kuhle, Antonio Laborante, Ivan Lombardi, Gianmarco Muzi, Francesca Paci, Giuliana Placentino, Teresa Popolizio, Claudia Ricciolini, Simonetta Sabatini, Giada Silveri, Cristina Spera, Daniel Stephenson, Giuseppe Stipa, Elettra Tinella, Michele Zarrelli, Chiara Zecca, Yendri Ventura, Angelo D'Alessandro, Luca Peruzzotti-Jametti, Stefano Pluchino, Angelo L Vescovi
We report the analysis of 1 year of data from the first cohort of 15 patients enrolled in an open-label, first-in-human, dose-escalation phase I study (ClinicalTrials.gov: NCT03282760, EudraCT2015-004855-37) to determine the feasibility, safety, and tolerability of the transplantation of allogeneic human neural stem/progenitor cells (hNSCs) for the treatment of secondary progressive multiple sclerosis. Participants were treated with hNSCs delivered via intracerebroventricular injection in combination with an immunosuppressive regimen...
December 7, 2023: Cell Stem Cell